Indo-National Reports Q2 & H1 FY25 Results; Shareholder Approval for Amalgamation
Indo-National reported Q2 & H1 FY25 results. Standalone profits increased, while consolidated profits were impacted by a high base. Shareholder approval received for Helios amalgamation and new investments were made.
The announcement includes the company's latest quarterly and half-yearly financial performance, which is a key indicator for investors. Additionally, significant corporate actions such as the ongoing amalgamation process and new strategic investments (one leading to a new subsidiary) are disclosed. These events have substantial implications for the company's future structure, growth prospects, and financial health, warranting a high impact rating.
The standalone financial results show an increase in profit before tax and profit for the period despite a slight dip in revenue. However, the consolidated profit figures for the half-year show a significant decline primarily due to an exceptionally high 'Other income' in the previous corresponding period, creating a challenging base effect. Positive corporate actions include shareholder approval for the amalgamation of Helios Strategic Systems and strategic investments in Medcuore Medical Solutions (making it a subsidiary) and Axial Aero. The ongoing CCI penalty case is a contingent liability, but no provision has been made based on legal opinion, indicating a neutral stance for now. The mixed financial performance and strategic corporate developments balance out to a neutral sentiment.
Indo-National Limited announced its unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2025, approved by the Board of Directors on October 29, 2025. * Standalone Performance (Q2 FY25 vs Q2 FY24): * Revenue from operations: ₹11906.90 lakhs, down from ₹12757.07 lakhs. * Profit before tax: ₹308.91 lakhs, up from ₹170.98 lakhs. * Profit for the period: ₹267.91 lakhs, up from ₹199.98 lakhs. * Basic and Diluted EPS: ₹3.57, up from ₹2.67. * Standalone Performance (H1 FY25 vs H1 FY24): * Revenue from operations: ₹23650.92 lakhs, down from ₹23923.05 lakhs. * Profit before tax: ₹483.27 lakhs, up from ₹280.23 lakhs. * Profit for the period: ₹430.27 lakhs, up from ₹301.23 lakhs. * Basic and Diluted EPS: ₹5.74, up from ₹4.02. * Consolidated Performance (Q2 FY25 vs Q2 FY24): * Revenue from operations: ₹11959.88 lakhs, down from ₹12757.07 lakhs. * Profit before tax: ₹150.13 lakhs, down from ₹187.55 lakhs. * Profit for the period: ₹109.13 lakhs, down from ₹216.55 lakhs. * Basic and Diluted EPS: ₹1.85, down from ₹2.89. * Consolidated Performance (H1 FY25 vs H1 FY24): * Revenue from operations: ₹23903.90 lakhs, down from ₹24872.43 lakhs. * Profit before tax: ₹268.93 lakhs, significantly down from ₹16631.92 lakhs due to a high 'Other income' base in the prior year. * Profit for the period: ₹215.93 lakhs, significantly down from ₹13393.45 lakhs for the same reason. * Basic and Diluted EPS: ₹3.21, significantly down from ₹181.00. * Amalgamation Update: The NCLT order dated April 29, 2025, directed a meeting of Equity Shareholders for the proposed amalgamation of Helios Strategic Systems Limited with Indo National Limited. The resolution was duly passed with the requisite majority on June 21, 2025, and is subject to further statutory and regulatory approvals. * Investments: During the half-year, the company invested ₹568.66 lakhs to acquire 46.76% in Medcuore Medical Solutions Private Limited, making it a subsidiary. Additionally, ₹850 lakhs were invested in Compulsory Convertible Preference Shares of Axial Aero Private Limited. * CCI Penalty: An appeal against a CCI penalty of ₹4,226 lakhs is pending before NCLAT, with ₹422 lakhs already deposited. No provision has been made for the period ended September 30, 2025, based on legal opinion.
What to do with a filing like this
Indo-National Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indo-National Limited. Read the original for the full detail.